Cargando…

Treatment of severe covid-19 with interleukin 6 receptor inhibition

Detalles Bibliográficos
Autores principales:	Rajasundaram, Skanda, Burgess, Stephen, Gill, Dipender
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978669/ https://www.ncbi.nlm.nih.gov/pubmed/36936584 http://dx.doi.org/10.1136/bmjmed-2022-000144

Ejemplares similares

Genetically proxied interleukin-6 receptor inhibition: opposing associations with COVID-19 and pneumonia
por: Larsson, Susanna C., et al.
Publicado: (2021)

Morning Cortisol and Circulating Inflammatory Cytokine Levels: A Mendelian Randomisation Study
por: Rajasundaram, Skanda, et al.
Publicado: (2022)

Adenosine A2A Receptor Signaling in the Immunopathogenesis of Experimental Autoimmune Encephalomyelitis
por: Rajasundaram, Skanda
Publicado: (2018)

TIE1 and TEK signalling, intraocular pressure, and primary open-angle glaucoma: a Mendelian randomization study
por: Rajasundaram, Skanda, et al.
Publicado: (2023)

Interleukin-6 Receptor Inhibition in Covid-19 — Cooling the Inflammatory Soup
por: Rubin, Eric J., et al.
Publicado: (2021)

Inhibition of interleukin 6 signalling and renal function: A Mendelian randomization study
por: Ryan, David K., et al.
Publicado: (2021)

Safety of beta-blocker and calcium channel blocker antihypertensive drugs in pregnancy: a Mendelian randomization study
por: Ardissino, Maddalena, et al.
Publicado: (2022)

Use of a Genetic Variant Related to Circulating FXa (Activated Factor X) Levels to Proxy the Effect of FXa Inhibition on Cardiovascular Outcomes
por: Gill, Dipender, et al.
Publicado: (2020)

Interleukin 6 inhibition in severe COVID-19: Another piece of the puzzle
por: Farina, Nicola, et al.
Publicado: (2022)

Implications for White Matter Vulnerability to Anti-interleukin-6 Receptor Antibody Treatment
por: Kato, Daisuke
Publicado: (2020)

Genetic evidence for vitamin D and cardiovascular disease: choice of variants is critical
por: Burgess, Stephen, et al.
Publicado: (2022)

The evolution of mendelian randomization for investigating drug effects
por: Gill, Dipender, et al.
Publicado: (2022)

Liver Injury and Elevated Levels of Interleukins, Interleukin-2 Receptor, and Interleukin-6 Predict the Severity in Patients With COVID-19
por: Luo, Kuan, et al.
Publicado: (2021)

Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome
por: Chen, Luke Y.C., et al.
Publicado: (2020)

Elevated interleukin‐6, interleukin‐10 and neutrophil : lymphocyte ratio as identifiers of severe coronavirus disease 2019
por: Godkin, Andrew, et al.
Publicado: (2020)

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation
por: Salvatierra, Juan, et al.
Publicado: (2021)

Systemic iron status and maternal pregnancy complications: A Mendelian randomization study
por: Rogne, Tormod, et al.
Publicado: (2022)

Measurement of Interleukin-6 Levels in COVID: Illuminative or Illogical?
por: Hegde, Ashit
Publicado: (2022)

The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?
por: Tatham, Kate C., et al.
Publicado: (2021)

Special issue on Interleukin-6 (IL-6)
por: Rincon, Mercedes
Publicado: (2012)

Interleukin-6 Signaling Effects on Ischemic Stroke and Other Cardiovascular Outcomes: A Mendelian Randomization Study
por: Georgakis, Marios K., et al.
Publicado: (2020)

Interleukin-6 and severity of COVID-19 patients in Hefei, China
por: Zhao, Z., et al.
Publicado: (2020)

The role of Interleukin 6 inhibitors in therapy of severe COVID-19
por: Nasonov, E., et al.
Publicado: (2020)

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2021)

Targeting interleukin-17 receptors
por: Lee, Wen-Hwa, et al.
Publicado: (2015)

Disentangling the effects of traits with shared clustered genetic predictors using multivariable Mendelian randomization
por: Batool, Fatima, et al.
Publicado: (2022)

An empirical investigation into the impact of winner’s curse on estimates from Mendelian randomization
por: Jiang, Tao, et al.
Publicado: (2022)

Interleukin-6 signaling in podocyte hypertrophy
por: Cha, Dae Ryong
Publicado: (2016)

Potential effects of itolizumab treatment on plasma interleukin-6 levels in patients with severe COVID-19
por: Vityala, Yethindra, et al.
Publicado: (2021)

Editorial: Tocilizumab, a Humanized Therapeutic IL-6 Receptor (IL-6R) Monoclonal Antibody, and Future Combination Therapies for Severe COVID-19
por: Parums, Dinah V.
Publicado: (2021)

Rethinking interleukin-6 blockade for treatment of COVID-19
por: Scherger, S., et al.
Publicado: (2020)

Genetically Proxied Inhibition of Coagulation Factors and Risk of Cardiovascular Disease: A Mendelian Randomization Study
por: Yuan, Shuai, et al.
Publicado: (2021)

Interleukin-6 inhibition in the treatment of autoinflammatory diseases
por: Koga, Tomohiro, et al.
Publicado: (2022)

The ubiquitous interleukin-6: a time for reappraisal
por: Fisman, Enrique Z, et al.
Publicado: (2010)

Interleukin-6: a local pain trigger?
por: Svensson, Camilla I
Publicado: (2010)

A role for interleukin-1 receptor antagonism in severe COVID-19?
por: Tattersall, Rachel S, et al.
Publicado: (2021)

Soluble interleukin-6 receptor in the COVID-19 cytokine storm syndrome
por: Chen, Luke Y.C., et al.
Publicado: (2021)

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
Publicado: (2021)

Interleukin-6: a promising target for the treatment of polymyalgia rheumatica or giant cell arteritis?
por: Toussirot, Éric, et al.
Publicado: (2016)

Genetic predisposition to allergic diseases is inversely associated with risk of COVID‐19
por: Larsson, Susanna C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l0gn8643v6clpjdomjn9htegfq